SynthesisRadiology and oncology2020
Perioperative radiotherapy versus surgery alone for retroperitoneal sarcomas: a systematic review and meta-analysis.
Synthesis in Radiology and oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Retroperitoneal Sarcoma (RPS): A Systematic Review.Current oncology reports · 2025Pooled it
- Preoperative radiotherapy combined with surgery versus surgery alone for primary retroperitoneal sarcoma: a meta-analysis.Scientific reports · 2025Pooled it
- Neoadjuvant radiotherapy for resectable retroperitoneal sarcoma: a meta-analysis.Radiation oncology (London, England) · 2022Pooled it
- Survival outcomes of surgery for retroperitoneal sarcomas: A systematic review and meta-analysis.PloS one · 2022Pooled it
- A case report of a rare retroperitoneal sarcoma in an adolescent.Urology case reports · 2026Article
- Heterogeneity in response to neoadjuvant radiotherapy between soft tissue sarcoma histotypes: associations between radiology and pathology findings.European radiology · 2025Article
- Potential benefits of neoadjuvant radiotherapy prior to "en bloc" compartmental resection of pure retroperitoneal liposarcomas.World journal of urology · 2024Article
- Survival and prognostic factors of primary retroperitoneal sarcomas after surgery: a single-center experience.Langenbeck's archives of surgery · 2024Article
- Radiation therapy for retroperitoneal sarcoma: practice patterns in North America.Radiation oncology (London, England) · 2024Article
- Review
- Multivisceral resection for retroperitoneal liposarcoma-is it worth it? A 20-year single-center experience.Surgery today · 2023Article
- The Role of Surgery in Oligometastatic Retroperitoneal Sarcoma.Current oncology (Toronto, Ont.) · 2023Review
- Superficial soft tissue sarcomas: 10‑year survival outcomes.Oncology letters · 2023Article
- Effect of pre-operative radiation therapy on surgical outcome in retroperitoneal sarcoma.Frontiers in surgery · 2023Article
- Nomogram predicting overall survival after surgical resection for retroperitoneal leiomyosarcoma patients.Frontiers in endocrinology · 2023Article
- Morbidity and Mortality after Surgery for Retroperitoneal Sarcoma.Current oncology (Toronto, Ont.) · 2022Review
- Landmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal Sarcoma.Annals of surgical oncology · 2022Review
- Retroperitoneal Sarcomas: a Current Review on Management.Indian journal of surgical oncology · 2022Review
- Factors associated with disease-free and abdominal recurrence-free survival in abdominopelvic and retroperitoneal sarcomas.Journal of surgical oncology · 2022Article
- Preoperative Biopsy in Patients with Retroperitoneal Sarcoma: Usage and Outcomes in a National Cohort.Annals of surgical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background There is no clear evidence on whether radiotherapy (RT) improves treatment result in patients with retroperitoneal sarcomas (RPS). Methods A systematic literature search was performed using PubMed, Scopus and CENTRAL databases. Data were retrieved from published comparatives studies in patients with RPS undergoing surgery alone or RT plus surgery. The primary endpoints were the 5-year OS and the median OS. The secondary endpoints were the recurrence-free survival (RFS) and the R0-resection rate. Continuous outcomes were calculated by means of weighted mean difference (WMD). Results Ten out of 374 articles were analyzed. The median OS and the 5-year survival were significantly increased in patients treated with RT and surgery, compared to patients treated with surgery alone (p < 0.00001, p < 0.001). Median RFS was significantly increased in patients treated with either preoperative (p < 0.001) or postoperative (p = 0.001) RT compared to patients that underwent surgery alone. Finally, median R0-resection rate was similar between the two groups (p = 0.56). Conclusion RT along with radical surgery could be the standard of care in at least a subgroup of patients with RPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.